Following miRNAs are related to cervical cancer
miRNA |
PubMed |
Host Gene |
Target Gene |
Location |
Fold Change |
Remark (Expression/ Alteration) |
---|---|---|---|---|---|---|
miR-218 | 20163849 | SLIT2 | LAMB3 | NA | NA | SLIT2 encodes miR-218 and are parally expressed but is a possible target of miR-200c. Its an SNP study to determine its effect on pathway (Reduced Expression) |
miR-218 | 17998940 | SLIT2 | LAMB3 | NA | -2 | microRNA-218 (miR-218) was specifically underexpressed in HPV-positive cell lines, cervical lesions and cancer tissues containing HPV-16 DNA (Reduced Expression) |
miR-199a | 18451214 | DNM2 | NA | NA | >100 in ISCC | can be a potential therapeutic target for cervical cancer. is the most upregulated in ISCC (Over Expression) |
miR-199a* | 18451214 | DNM2 | NA | NA | >100 in ISCC | (Over Expression) |
miR-199-s | 18451214 | DNM2 | NA | NA | >100 in ISCC | (Over Expression) |
miR-21 | 17616659 | NA | PDCD4 | 17q23.2 | NA | 13-45% were found in cancer group, whereas 3-12% were identified in normal .is the only miRNA over-expressed in more than 11 types of solid tumors stomach,prostate,head and neck, esophogous, glipblastoma, neuroblastoma,cholangiocarcinoma, brest, lung,coroectal and pancreatic cancer (Over Expression) |
miR-21 | 19682430 | NA | PDCD4 | NA | NA | is the only miRNA over-expressed in more than 11 types of solid tumors stomach,prostate,head and neck, esophogous, glipblastoma, neuroblastoma,cholangiocarcinoma, brest, lung,coroectal and pancreatic cancer (Over Expression) |
miR-34a | 20351093 | NA | Notch1, Jagged1 | 1p36.23 | NA | miR-34a was expresssed in all the cell lines. Its expression levels in HeLa and C33a were very similar, whilw expression (Reduced Expression) |
miR-200a | 20124485 | NA | MYH10, ZEB1, DCP2, YWHAG, KIDINS220, ZEB2, TGFB2, RANBP5, EXOC5 | NA | NA | It simultaneously targets multiple genes (Over Expression) |
miR-214 | 19859982 | NA | MEK3, JNK1 | NA | Down regulates to 25.6-63.2% | Is a negative regulator of cell growth (Reduced Expression) |
hsa-miR-124 | 20579385 | NA | IGFBP7 | 8p23.1, 8p12.3, 20q13.33 | NA | Reduced Expression |
miR-143 | 17616659 | NA | ERK5 (MAPK7) | NA | NA | significantly reduced |
miR-934 | 17616659 | NA | NA | Xq26.3 | NA | NA |
miR-374b | 17616659 | NA | NA | Xq13.2 | NA | NA |
miR-937 | 17616659 | NA | NA | 8q24.3 | NA | NA |
miR-939 | 17616659 | NA | NA | 8q24.3 | NA | NA |
miR-671 | 17616659 | NA | NA | 7q36.1 | NA | NA |
miR-874-5p | 17616659 | NA | NA | 5q31.2 | NA | NA |
miR-943 | 17616659 | NA | NA | 4p16.3 | NA | NA |
miR-944 | 17616659 | NA | NA | 3q28 | NA | NA |
miR-933 | 17616659 | NA | NA | 2q31.1 | NA | NA |
miR-941 | 17616659 | NA | NA | 20q13.33 | NA | NA |
miR-942 | 17616659 | NA | NA | 1p13.1 | NA | NA |
miR-935 | 17616659 | NA | NA | 19q13.42 | NA | NA |
miR-769-3p | 17616659 | NA | NA | 19q13.32 | NA | NA |
miR-940 | 17616659 | NA | NA | 16p13.3 | NA | NA |
miR-708 | 17616659 | NA | NA | 11q14.1 | NA | NA |
miR-936 | 17616659 | NA | NA | 10q25.1 | NA | NA |
miR-938 | 17616659 | NA | NA | 10p11.23 | NA | NA |
miR-203 | 18451214 | NA | NA | NA | 3.704 in ISCC | (Down Regulation) |
miR-149 | 18451214 | NA | NA | NA | 2.974 in ISCC | (Down Regulation) |
miR-127 | 18451214 | NA | NA | NA | >100 in ISCC | The expression of miR-127 increase significantly in patient with lymph node metastatis (Over Expression) |
miR-133a | 18451214 | NA | NA | NA | >100 in ISCC | Over Expression |
miR-133b | 18451214 | NA | NA | Over Expression | >100 in ISCC | Over Expression |
miR-145 | 18451214 | NA | NA | NA | >100 in ISCC | Over Expression |
miR-199b | 18451214 | NA | NA | NA | >100 in ISCC | Over Expression |
miR-214 | 18451214 | NA | NA | NA | >100 in ISCC | Over Expression |
miR-9 | 18451214 | NA | NA | NA | >100 in ISCC | Over Expression |
HMP- PREDICTED -MIR112 | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
HMP- PREDICTED -MIR128 | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
HMP- PREDICTED -MIR158 | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
HMP- PREDICTED -MIR189 | 20149030 | NA | NA | NA | NA | expressed significantly higher in SCC than NT group |
HMP- PREDICTED -MIR19 | 20149030 | NA | NA | NA | NA | only expressed in NT samples |
HMP- PREDICTED -MIR234 | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
HMP- PREDICTED -MIR235 | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
HMP- PREDICTED -MIR61 | 20149030 | NA | NA | NA | NA | expressed significantly lower in SCC than NT group |
hsa-let-7a | 20149030 | NA | NA | NA | NA | expressed significantly lower in SCC than NT group |
hsa-let-7b | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
hsa-let-7c | 20149030 | NA | NA | NA | NA | expressed significantly higher in SCC than NT group |
hsa-let-7d | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
hsa-let-7e | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
hsa-let-7f | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
hsa-miR-184 | 20149030 | NA | NA | NA | NA | only expressed in NT samples |
hsa-miR-202 | 20149030 | NA | NA | NA | NA | expressed significantly higher in SCC than NT group |
hsa-miR-21 | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
hsa-miR-214 | 20149030 | NA | NA | NA | NA | only expressed in NT samples |
hsa-miR-26a | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
hsa-miR-31 | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
hsa-miR-494 | 20149030 | NA | NA | NA | NA | expressed significantly lower in SCC than NT group |
hsa-miR-501 | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
hsa-miR-515-3p | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
mmu-miR-140 | 20149030 | NA | NA | NA | NA | only expressed in NT samples |
mmu-miR-298 | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
mmu-miR-469 | 20149030 | NA | NA | NA | NA | only expressed in NT samples |
rno-miR-352 | 20149030 | NA | NA | NA | NA | only expressed in SCC samples |
miR-9 | 20124485 | NA | NA | NA | NA | Over Expression |
miR-34a | 19258450 | NA | NA | NA | NA | miR-34a was identified as a direct transcriptionaltarget of cellular transcription factor p53.This transactivation of miR-34a expression is triggered by the binding of p53 to a consensus p53 binding site identified in the miR-34a promoter region. Since HPV E6 oncoprotein destabilizes p53 during virus infection, one may assume a down-regulation of miR-34a expression in most cervical cancer tissues with oncogenic HPV infection (Reduced Expression) |
let-7f | 18596939 | NA | NA | NA | NA | Increased Expression |
miR-100 | 18596939 | NA | NA | NA | NA | Reduced Expression |
miR-125b | 18596939 | NA | NA | NA | NA | Reduced Expression |
miR-126 | 18596939 | NA | NA | NA | NA | Reduced Expression |
miR-155 | 18596939 | NA | NA | NA | NA | Increased Expression |
miR-15a | 18596939 | NA | NA | NA | NA | Increased Expression |
miR-15b | 18596939 | NA | NA | NA | NA | Increased Expression |
miR-16 | 18596939 | NA | NA | NA | NA | Increased Expression |
miR-195 | 18596939 | NA | NA | NA | NA | Reduced Expression |
miR-199a | 18596939 | NA | NA | NA | NA | Reduced Expression |
miR-205 | 18596939 | NA | NA | NA | NA | Increased expression in cancer cell line except SiHa(HPV16+), HeLa(HPV18+), and C33A(HPV-) as compared to normal cervical tissue, while these have no expression (Increased Expression) |
miR-205 | 18596939 | NA | NA | NA | NA | Increased Expression |
miR-21 | 18596939 | NA | NA | NA | NA | Over Expression |
miR-21 | 18596939 | NA | NA | NA | NA | Increased Expression |
miR-223 | 18596939 | NA | NA | NA | NA | Increased Expression |
miR-24 | 18596939 | NA | NA | NA | NA | Over Expression |
miR-26a | 18596939 | NA | NA | NA | NA | Reduced Expression |
miR-27a | 18596939 | NA | NA | NA | NA | Reduced Expression |
miR-29a | 18596939 | NA | NA | NA | NA | Reduced Expression |
miR-424 | 18596939 | NA | NA | NA | NA | Reduced Expression |
miR-99a | 18596939 | NA | NA | NA | NA | Reduced Expression |
let-7a | 17998940 | NA | NA | NA | NA | Highly Expressed in Normal |
let-7b | 17998940 | NA | NA | NA | NA | Highly Expressed in Normal |
let-7c | 17998940 | NA | NA | NA | NA | Highly Expressed in Normal |
miR-1 | 17998940 | NA | NA | NA | NA | Expressed in Normal |
miR-125b | 17998940 | NA | NA | NA | NA | Highly Expressed in Normal |
miR-126 | 17998940 | NA | NA | NA | NA | Most Highly Expressed in Normal |
miR-133b | 17998940 | NA | NA | NA | NA | Expressed in Normal |
miR-143 | 17998940 | NA | NA | NA | NA | Most Highly Expressed in Normal |
miR-145 | 17998940 | NA | NA | NA | NA | Most Highly Expressed in Normal |
miR-182 | 17998940 | NA | NA | NA | NA | Over Expressed |
miR-183 | 17998940 | NA | NA | NA | NA | Over Expressed |
miR-195 | 17998940 | NA | NA | NA | NA | Most Highly Expressed in Normal |
miR-210 | 17998940 | NA | NA | NA | NA | Over Expressed |
miR-214 | 17998940 | NA | NA | NA | NA | Expressed in normal |
miR-26a | 17998940 | NA | NA | NA | NA | Highly Expressed in Normal |
miR-368 | 17998940 | NA | NA | NA | NA | Expressed in normal |
miR-451 | 17998940 | NA | NA | NA | NA | Expressed in normal |
miR-7029 | 17998940 | NA | NA | NA | NA | Expressed in normal |
miR-99a | 17998940 | NA | NA | NA | NA | Highly Expressed in normal |
let-7b | 17616659 | NA | NA | NA | NA | Significantly Reduced |
let-7c | 17616659 | NA | NA | NA | NA | a frequency of 15-18% in normal cervical sample compare with no detection in three cell lines ,0.2% -0.4% IN TWO LINES AND 7.2% IN ONE (Significantly Reduced) |
miR-196b | 17616659 | NA | NA | NA | NA | 1-2% in normal cervical samples whereas only 0.1 in cancer cells (Significantly Reduced) |
miR-23b | 17616659 | NA | NA | NA | NA | Significanlty Reduced |
miR-874-3p | 17616659 | NA | NA | NA | NA | NA |
ambi_miR_13143 | 17998940 | NA | NA | NA | >320.8 | Over Expression |
hsa_miR_31 | 17998940 | NA | NA | NA | >13.7 | Over Expression |
hsa_miR_106a | 17998940 | NA | NA | NA | >12.2 | Over Expression |
hsa_miR_93 | 17998940 | NA | NA | NA | >8.9 | Over Expression |
ambi_miR_9630 | 17998940 | NA | NA | NA | >7.1 | Over Expression |
hsa_miR_17_5p | 17998940 | NA | NA | NA | >6.6 | Over Expression |
hsa_miR_182 | 17998940 | NA | NA | NA | >6.5 | Over Expression |
hsa_miR_196a | 17998940 | NA | NA | NA | >6.2 | Over Expression |
miR-146a | 18596939 | NA | NA | NA | >6 | Increased Expression |
hsa_miR_30a_5p | 17998940 | NA | NA | NA | >5.6 | Over Expression |
hsa_miR_183 | 17998940 | NA | NA | NA | >5.2 | Over Expression |
hsa_miR_25 | 17998940 | NA | NA | NA | NA | Over Expression |
hsa_miR_106b | 17998940 | NA | NA | NA | >4.4 | Over Expression |
hsa_miR_224 | 17998940 | NA | NA | NA | >3.6 | Over Expression |
miR-143 | 18596939 | NA | NA | NA | >2.7 | miR-143 and miR-145 are expressed from the same miRNA precursor (Reduced Expression) |
miR-145 | 18596939 | NA | NA | NA | >2.7 | Reduced Expression |
hsa_miR_139 | 17998940 | NA | NA | NA | > -3.3 | Reduced Expression |
hsa_miR_200c | 17998940 | NA | NA | NA | > -3.7 | Reduced Expression |
hsa_miR_200a | 17998940 | NA | NA | NA | > -4.6 | Reduced Expression |
hsa_miR_329 | 17998940 | NA | NA | NA | > -4.6 | Reduced Expression |
hsa_miR_451 | 17998940 | NA | NA | NA | > -5.3 | Reduced Expression |
hsa_miR_368 | 17998940 | NA | NA | NA | > -5.6 | Reduced Expression |
hsa_miR_199a | 17998940 | NA | NA | NA | > -5.7 | Reduced Expression |
hsa_miR_214 | 17998940 | NA | NA | NA | > -6.7 | Reduced Expression |
hsa_miR_143 | 17998940 | NA | NA | NA | > -6.8 | Reduced Expression |
hsa_miR_133b | 17998940 | NA | NA | NA | > -7.6 | Reduced Expression |
hsa_miR_205 | 17998940 | NA | NA | NA | > -8 | Reduced Expression |
ambi_miR_7029 | 17998940 | NA | NA | NA | > -8.4 | Reduced Expression |
hsa_miR_145 | 17998940 | NA | NA | NA | > -9.1 | Reduced Expression |
hsa_miR_1 | 17998940 | NA | NA | NA | > -9.3 | Reduced Expression |